HOME
ANZ BCTG PROFILE
NEWS AND MEDIA RELEASES
CLINICAL TRIALS
Prevention
Early Breast Cancer
Advanced
ANNUAL PARTICIPANTS' SCIENTIFIC MEETING
CONSUMER ADVISORY PANEL
BREAST CANCER INSTITUTE OF AUSTRALIA
POSITIONS VACANT
USEFUL LINKS
BECOME A MEMBER
CONTACT INFORMATION
SEARCH
LOGIN
Username :
Password :
Forgot Your Password?
Printer Friendly
Early
ANZ 0702 / BIG 2-06 : ALTTO - Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study
A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
ANZ 0901 / PACCT - 1 : TAILORx - Trial Assigning IndividuaLized Options for Treatment
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
IBCSG 22-00 : Maintenance Chemotherapy
Low dose cytotoxics as anti-angiogenesis treatment following adjuvant induction chemotherapy for patients with ER-Negative and PgR negative breast cancer.
IBCSG 25-02 / BIG 3-02 : TEXT - Tamoxifen and Exemestane Trial
A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer.
IBCSG 34-05 / SWOG S0230 : POEMS - Prevention Of Early Menopause Study
Phase III trial of LHRH analogue administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormonal receptor-negative breast cancer.
IBCSG 35-07 / BIG 1-07 : SOLE - Study Of Letrozole Extension
A Phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years or prior adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, node-positive early stage breast cancer.
ANZ BCTG receives research infrastructure funding from the Cancer Institute NSW
and the Australian Government through Cancer Australia
Copyright ©
2010
Australian New Zealand Breast Cancer Trials Group Limited. All Rights Reserved.
Copyright & Disclaimer
|
Privacy Policy